September 26, 2007

Hon. Dave Hancock
Legislature Office
#204 Legislature Building
10800 - 97 Avenue
Edmonton, AB
T5K 2B6

Dear Minister Hancock:

In an effort to work collaboratively with government, Arthritis Consumer Experts and the Canadian Arthritis Patient Alliance are writing to bring your attention to the June 20, 2007 Common Drug Review’s Canadian Expert Drug Advisory Committee (CEDAC) recommendation that adalimumab (Humira®) be added to provincial drug benefit plans for people with active ankylosing spondylitis, who have had an inadequate response to at least three different nonsteroidal anti-inflammatory drugs (NSAIDS) and, in patients with peripheral joint involvement who have failed to respond to methotrexate or sulfasalazine (See attached CEDAC recommendation.)

Currently, Albertans living with ankylosing spondylitis have no biologic medications available to them on the provincial drug reimbursement formulary. Adalimumab (Humira®) has been under review since approximately November 2006 yet has still not been approved. The situation is the same for the other two biologic response modifiers on the market that have all been under review for significant periods of time. This continues to be unacceptable to the arthritis community and should be to the Government of Alberta, too.
As clearly outlined in the CEDAC recommendation, adalimumab not only “resulted in significantly more patients achieving ASAS 20, 50 and 70 after 12 weeks of treatment” but also improved quality of life, reduced disease activity and was shown to be cost effective.

Given this strong CEDAC recommendation and your Ministry’s support for the Common Drug Review process, we urge you, as Minister of Health, to take the immediate necessary steps to have adalimumab listed on the provincial drug benefit plan for people with ankylosing spondylitis. We remind you that this therapy is intended to treat Albertans with ankylosing spondylitis. Providing a timely reimbursement listing for this medication will ensure that Albertans living with ankylosing spondylitis are able to reduce the pain and disability associated with delaying treatment and improve their quality of life.

We thank you in advance for considering our request, and await word from you on Alberta’s listing decision for adalimumab for ankylosing spondylitis.

Sincerely,

Cheryl Koehn             Anne Dooley
President, Arthritis Consumer Experts    President, Canadian Arthritis Patient Alliance
Person with rheumatoid arthritis       Person with rheumatoid arthritis

Encl.

C.c. Glen Monteith, Directory Pharmaceutical Policy and Programs Branch

Note: Please address reply correspondence to Ms. Cheryl Koehn, Arthritis Consumer Experts, 910 B Richards Street, Vancouver, BC V6B 3C1; or, Anne Dooley, 206 Garrison Crescent, Saskatoon, SK. S7H 2Z8